Genomics,Multiomics

Dataset Information

98

EZH2 inhibitor efficacy in non-Hodgkin lymphoma does not require suppression of H3K27 mono-methylation [ChIP-Seq]


ABSTRACT: Here we report the discovery of highly potent and selective EZH2 small molecule inhibitors, their validation by a cellular thermal shift assay, their application across a large lymphoma cell panel and their efficacy in GCBDLBCL xenograft models. Baseline ChIP-seq measurement of KARPAS-422 cell line H3K27me3 levels, without treatment. Two samples -- H3K27me3 and Input included as control.

ORGANISM(S): Homo sapiens  

SUBMITTER: Barbara M Bryant  Charlie Hatton   William D Bradley   Patrick Trojer   Feng Zhao   Shivani Garapaty-Rao    

PROVIDER: E-GEOD-62057 | ArrayExpress | 2015-08-19

SECONDARY ACCESSION(S): SRP048641GSE62057PRJNA263116

REPOSITORIES: GEO, ArrayExpress, ENA

altmetric image

Publications


The histone lysine methyltransferase (MT) Enhancer of Zeste Homolog 2 (EZH2) is considered an oncogenic driver in a subset of germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) and follicular lymphoma due to the presence of recurrent, monoallelic mutations in the EZH2 catalytic domain. These genomic data suggest that targeting the EZH2 MT activity is a valid therapeutic strategy for the treatment of lymphoma patients with EZH2 mutations. Here we report the identification of hi  ...[more]

Similar Datasets

2015-08-19 | E-GEOD-62056 | ArrayExpress
2016-02-22 | E-GEOD-71739 | ArrayExpress
2016-01-09 | E-GEOD-71909 | ArrayExpress
2013-06-21 | E-GEOD-46945 | ArrayExpress
2015-03-16 | E-GEOD-53620 | ArrayExpress
2014-05-03 | E-GEOD-47484 | ArrayExpress
2015-11-28 | E-GEOD-54580 | ArrayExpress
2014-12-10 | E-GEOD-56693 | ArrayExpress
2013-03-11 | E-GEOD-41239 | ArrayExpress
2014-12-10 | E-GEOD-56692 | ArrayExpress